Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 3/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL454698 | 0.81 | TAAR1 (0.52) | TAAR1ESR2TNKS2CYP11B2CYP17A1 | |
| SCHEMBL512908 | 0.81 | ACHE (0.42) | ACHEPGRMAP4K4 | |
| SCHEMBL510184 | 0.78 | ACHE (0.40) | TNKS2ACHEPTPN1 | |
| SCHEMBL15063650 | 0.78 | METAP2 (0.35) | CYP3A4 | |
| SCHEMBL15064180 | 0.78 | TAAR1 (0.48) | TAAR1ESR2TNKS2CYP11B2CYP17A1 | |
| SCHEMBL15063974 | 0.78 | TAAR1 (0.48) | TAAR1ESR2TNKS2CYP11B2CYP17A1 | |
| SCHEMBL513430 | 0.78 | ESR2 (0.51) | TAAR1ESR2PGR | |
| SCHEMBL458915 | 0.78 | TAAR1 (0.48) | TAAR1ESR2TNKS2CYP11B2CYP17A1 | |
| SCHEMBL15063387 | 0.78 | NPC1 (0.42) | PGR | |
| SCHEMBL15063952 | 0.77 | TAAR1 (0.46) | TAAR1ESR2TNKS2ACHEPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114615969-A | Novel process | 帝斯曼知识产权资产管理有限公司 | 2022-06-10 | — | — | CN | claimed |
| CN-107835680-B | Novel selective 11-beta-hydroxysteroid dehydrogenase type 1 | 帝斯曼知识产权资产管理有限公司 | 2021-11-09 | — | — | CN | disclosed |
| EP-3045450-B1 | INTERMEDIATE COMPOUNDS IN PROCESSES FOR PRODUCING PYRIDAZINONE COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2018-02-07 | — | — | EP | disclosed |
| EP-3045450-A1 | INTERMEDIATE COMPOUNDS IN A PROCESS FOR PRODUCING PYRIDAZINONE COMPOUNDS | SUMITOMO CHEMICAL CO., LTD. (JP) | 2016-07-20 | — | — | EP | disclosed |
| EP-2614053-B1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATES THEREOF | SUMITOMO CHEMICAL CO (JP) | 2016-03-23 | — | — | EP | disclosed |
| US-9040709-B2 | Method for producing pyridazinone compounds and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140378688-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2014-12-25 | — | — | US | disclosed |
| US-8884010-B2 | Method for producing pyridazinone compounds and intermediate thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-11-11 | — | — | US | disclosed |
| EP-2614053-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-20130172556-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-07-04 | — | — | US | disclosed |
| WO-2012033225-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-03-15 | — | — | WO | disclosed |
| US-20120028988-A1 | USE OF PYRIDAZINONE COMPOUND FOR CONTROL OF HARMFUL ARTHROPOD PESTS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172556-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | PDXK, DHPS, NQO1 | TAAR1 2943/4885ESR2 3874/4885TNKS2 1022/4885 |
| US-20120028988-A1 | USE OF PYRIDAZINONE COMPOUND FOR CONTROL OF HARMFUL ARTHROPOD PESTS | PLPBP, PNPO, PIR | TAAR1 352/4885ESR2 4826/4885TNKS2 2772/4885 |
| US-20140378688-A1 | METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF | PDXK, DHPS, NQO1 | TAAR1 2943/4885ESR2 3874/4885TNKS2 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.